Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

Opus Genetics has successfully finished enrolling patients for the registrational Phase 3 trial of OPGx-LCA5 to treat LCA5-linked Inherited Retinal Disease. This major milestone marks the completion of patient recruitment for the trial, bringing the total number of participants to the designated capacity required for the study. OPGx-LCA5 aims to offer a revolutionary treatment option for individuals affected by LCA5-associated Inherited Retinal Disease, addressing an unmet medical need. The completion of patient enrollment sets the stage for the next phase of the trial, which will assess the efficacy and safety of OPGx-LCA5 in treating this rare genetic condition.